Skip to content
Screener

Regeneron Pharmaceuticals REGN Q3 2025 earnings

Reported October 28, 2025 · Before market open

Revenue$3.8BBeat by $162.1M
EPS$11.83Beat by $2.18
Revenue estimate$3.6B
EPS estimate$9.65

Next report

Oct 30, 2026 (In 3 weeks)
Revenue estimate$4.5B
EPS estimate$15.99

Financials

Q3 2025

Income statement

See full
Revenue$3.8B+0.9%
Operating income$1.0B-12.9%
Net income$1.5B+8.9%
EPS (diluted)$13.62+18.0%

Balance sheet

See full
Cash & equivalents$2.5B+24.9%
Total debt$2.7B+0.1%
Total equity$31.0B+5.6%
Total assets$40.2B+7.3%

Cash flow

See full
Operating cash flow$1.6B+25.4%
CapEx$201.4M-16.7%
Free cash flow$1.4B+35.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$59.59B-47.6%
Enterprise value$59.79B-47.7%
P/E13×-11.4×
P/S4.2×-4.0×

Profitability

See full
Operating margin25.9%-2.8pp
Net margin32.1%-1.5pp
FCF margin29.6%+4.8pp

Returns & leverage

See full
Return on equity15.2%-2.0pp
Debt / equity0.1×0.0×
Current ratio4.1×-1.2×

FAQ

When did Regeneron Pharmaceuticals report Q3 2025 earnings?
Regeneron Pharmaceuticals (REGN) reported Q3 2025 earnings on October 28, 2025 before market open.
What were Regeneron Pharmaceuticals's Q3 2025 revenue and EPS?
Regeneron Pharmaceuticals reported revenue of $3.8B and eps of $11.83 for Q3 2025.
Did Regeneron Pharmaceuticals beat estimates in Q3 2025?
Revenue beat the consensus estimate of $3.6B by $162.1M. EPS beat the consensus estimate of $9.65 by $2.18.
How did Regeneron Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.9% from $3.7B a year earlier and eps declined 5.1% from $12.46.
Where can I find Regeneron Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0000872589-25-000026) and the 10-Q periodic report (0000872589-25-000028) directly on SEC EDGAR. The filing index links above go to sec.gov.